New cancer drug FP008 enters first human trial

NCT ID NCT06990698

First seen Nov 01, 2025 · Last updated Jun 10, 2026 · Updated 28 times

Summary

This early-phase study tests a new drug called FP008 in 108 adults with advanced solid tumors. The main goal is to check the drug's safety and find the right dose. Researchers will also look at how the drug moves through the body and whether it helps shrink tumors. This is a first step to see if FP008 might be a future treatment option.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMORS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Hubei Cancer Hospital

    RECRUITING

    Wuhan, Hubei, 430014, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Shanxi Cancer Hospital

    RECRUITING

    Taiyuan, Shanxi, 030013, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Zhejiang Cancer Hospital

    RECRUITING

    Hangzhou, Zhejiang, 310022, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.